@liliyanglab.bsky.social
Pinned
Serotonin transporter inhibits antitumor immunity through regulating the intratumoral serotonin axis
Serotonin transporter (SERT) inhibits CD8 T cell antitumor immunity by depleting intratumoral
serotonin. SERT-blocking selective serotonin reuptake inhibitor (SSRI) antidepressants
enhance CD8 T cell ...
www.cell.com
Can serotonin and SSRIs help T cells kill cancer?
Our @cp-cell.bsky.social article by Dr. Bo Li, doctoral candidate James Elsten-Brown and their team reports "Serotonin transporter inhibits antitumor immunity through regulating the intratumoral serotonin axis!" www.cell.com/cell/fulltex...
Our @cp-cell.bsky.social article by Dr. Bo Li, doctoral candidate James Elsten-Brown and their team reports "Serotonin transporter inhibits antitumor immunity through regulating the intratumoral serotonin axis!" www.cell.com/cell/fulltex...
Another week, another #TylerTuesday! This Tuesday, Tyler is knocking out mesothelin in his tumor models. Good luck, Tyler!
July 1, 2025 at 9:41 PM
Another week, another #TylerTuesday! This Tuesday, Tyler is knocking out mesothelin in his tumor models. Good luck, Tyler!
Congrats to PhD CANDIDATE John Zhu for passing his oral qualifying exams today! Proud of you, John!
June 26, 2025 at 12:28 AM
Congrats to PhD CANDIDATE John Zhu for passing his oral qualifying exams today! Proud of you, John!
Happy #TylerTuesday everyone! Hope you're all having a great week🫀
June 17, 2025 at 11:13 PM
Happy #TylerTuesday everyone! Hope you're all having a great week🫀
Reposted
ICYMI: SSRIs Elevate Intratumoral Serotonin and Enhance Antitumor Immunity, a #ResearchWatch summary of a new study by Dr. Bo Li, @liliyanglab.bsky.social, and colleagues at @dgsomucla.bsky.social @uclastemcell.bsky.social
aacrjournals.org/cdnews/news/...
aacrjournals.org/cdnews/news/...
SSRIs Elevate Intratumoral Serotonin and Enhance Antitumor Immunity
Major Finding: Serotonin transporter depletes intratumoral serotonin which dampens CD8+ T-cell antitumor immunity.Concept: Serotonin transporter inhibition with SSRIs drives T-cell antitumor immunity ...
aacrjournals.org
June 11, 2025 at 4:24 PM
ICYMI: SSRIs Elevate Intratumoral Serotonin and Enhance Antitumor Immunity, a #ResearchWatch summary of a new study by Dr. Bo Li, @liliyanglab.bsky.social, and colleagues at @dgsomucla.bsky.social @uclastemcell.bsky.social
aacrjournals.org/cdnews/news/...
aacrjournals.org/cdnews/news/...
Congratulations to Sean Shen for passing his oral qualifying exams and becoming a PhD Candidate! We're proud of you, Sean!
June 4, 2025 at 7:27 PM
Congratulations to Sean Shen for passing his oral qualifying exams and becoming a PhD Candidate! We're proud of you, Sean!
It's #TylerTuesday!
Last week PhD Candidate Tyler Halladay shared his research on Engineering iPSC-derived gdT cells for solid tumor therapy with his UCLA Pharmacology community. Thanks for being a great representative of our lab, Tyler!
Last week PhD Candidate Tyler Halladay shared his research on Engineering iPSC-derived gdT cells for solid tumor therapy with his UCLA Pharmacology community. Thanks for being a great representative of our lab, Tyler!
May 27, 2025 at 5:19 PM
It's #TylerTuesday!
Last week PhD Candidate Tyler Halladay shared his research on Engineering iPSC-derived gdT cells for solid tumor therapy with his UCLA Pharmacology community. Thanks for being a great representative of our lab, Tyler!
Last week PhD Candidate Tyler Halladay shared his research on Engineering iPSC-derived gdT cells for solid tumor therapy with his UCLA Pharmacology community. Thanks for being a great representative of our lab, Tyler!
Reposted
Congrats to Dr. Bo Li and James Elsten-Brown on earning second place in UCLA TDG's #LABEST2025 poster competition for their work on SERT regulation of serotonin-dependent antitumor immunity, based on their research in doi.org/10.1016/j.ce...
Way to go, boys!
Way to go, boys!
May 23, 2025 at 12:55 AM
Congrats to Dr. Bo Li and James Elsten-Brown on earning second place in UCLA TDG's #LABEST2025 poster competition for their work on SERT regulation of serotonin-dependent antitumor immunity, based on their research in doi.org/10.1016/j.ce...
Way to go, boys!
Way to go, boys!
Reposted
This #WorldOvarianCancerDay, we highlight the work of Dr. Sanaz Memarzadeh and Dr. Lili Yang, who have teamed up to develop a novel immunotherapy they hope will transform ovarian cancer treatment. ➡️ bit.ly/3XsEVBS
UCLA researchers unite to develop immunotherapy they hope will transform ovarian cancer treatment
For decades, the story of ovarian cancer treatment has often followed the same pattern: surgery, chemotherapy, recurrence, repeat.This was the grim reality Dr. Sanaz Memarzadeh encountered as a second...
bit.ly
May 9, 2025 at 12:17 AM
This #WorldOvarianCancerDay, we highlight the work of Dr. Sanaz Memarzadeh and Dr. Lili Yang, who have teamed up to develop a novel immunotherapy they hope will transform ovarian cancer treatment. ➡️ bit.ly/3XsEVBS
Reposted
A UCLA study suggests that common antidepressants could enhance the immune system’s ability to fight #cancer and suppress tumor growth. Repurposing these existing FDA-approved drugs could speed up the process of bringing new cancer treatments to patients. stemcell.ucla.edu/news/common-...
Common antidepressants could help the immune system fight cancer, UCLA study finds
A widely used antidepressant drug could help the immune system fight cancer, according to a new UCLA research study.Selective serotonin reuptake inhibitors, or SSRIs, significantly enhanced the abilit...
stemcell.ucla.edu
May 21, 2025 at 4:39 PM
A UCLA study suggests that common antidepressants could enhance the immune system’s ability to fight #cancer and suppress tumor growth. Repurposing these existing FDA-approved drugs could speed up the process of bringing new cancer treatments to patients. stemcell.ucla.edu/news/common-...
Reposted
UCLA researchers led by Dr. Lili Yang have discovered a promising new method to treat myeloid malignancies, a group of blood cancers, using off-the-shelf CAR-NKT cells. Learn more this #WorldCancerDay how this study could improve patient outcomes: bit.ly/4hLW0yf
February 5, 2025 at 12:30 AM
UCLA researchers led by Dr. Lili Yang have discovered a promising new method to treat myeloid malignancies, a group of blood cancers, using off-the-shelf CAR-NKT cells. Learn more this #WorldCancerDay how this study could improve patient outcomes: bit.ly/4hLW0yf
Reposted
Lili Yang, UCLA leverages the power of hematopoietic stem cells to generate CAR-NKT for immunotherapy
Harnessing Stem Cells for Off-The-Shelf CAR-NKT Cell Therapy
Harnessing Stem Cells for Off-The-Shelf CAR-NKT Cell Therapy
May 4, 2025 at 2:31 AM
Lili Yang, UCLA leverages the power of hematopoietic stem cells to generate CAR-NKT for immunotherapy
Harnessing Stem Cells for Off-The-Shelf CAR-NKT Cell Therapy
Harnessing Stem Cells for Off-The-Shelf CAR-NKT Cell Therapy
Reposted
Now online! Serotonin transporter inhibits antitumor immunity through regulating the intratumoral serotonin axis
Serotonin transporter inhibits antitumor immunity through regulating the intratumoral serotonin axis
Serotonin transporter (SERT) inhibits CD8 T cell antitumor immunity by depleting intratumoral serotonin. SERT-blocking selective serotonin reuptake inhibitor (SSRI) antidepressants enhance CD8 T cell antitumor immunity and synergize with anti-PD-1, highlighting SSRIs as potential cancer immunotherapeutics.
dlvr.it
May 21, 2025 at 3:00 PM
Now online! Serotonin transporter inhibits antitumor immunity through regulating the intratumoral serotonin axis
Reposted
I’m a very lucky person 👍
‼️ @uclaupdates.bsky.social Reports: Who's the team behind identifying serotonin transporter as a tumor immunotherapy target? Dr. Bo Li leads a team of post-docs, grad students and undergrads in identifying immune checkpoints. And of course our lab manager Jie Huang! newsroom.ucla.edu/stories/anti...
May 22, 2025 at 1:27 AM
I’m a very lucky person 👍
‼️ @uclaupdates.bsky.social Reports: Who's the team behind identifying serotonin transporter as a tumor immunotherapy target? Dr. Bo Li leads a team of post-docs, grad students and undergrads in identifying immune checkpoints. And of course our lab manager Jie Huang! newsroom.ucla.edu/stories/anti...
May 22, 2025 at 1:05 AM
‼️ @uclaupdates.bsky.social Reports: Who's the team behind identifying serotonin transporter as a tumor immunotherapy target? Dr. Bo Li leads a team of post-docs, grad students and undergrads in identifying immune checkpoints. And of course our lab manager Jie Huang! newsroom.ucla.edu/stories/anti...
Can serotonin and SSRIs help T cells kill cancer?
Our @cp-cell.bsky.social article by Dr. Bo Li, doctoral candidate James Elsten-Brown and their team reports "Serotonin transporter inhibits antitumor immunity through regulating the intratumoral serotonin axis!" www.cell.com/cell/fulltex...
Our @cp-cell.bsky.social article by Dr. Bo Li, doctoral candidate James Elsten-Brown and their team reports "Serotonin transporter inhibits antitumor immunity through regulating the intratumoral serotonin axis!" www.cell.com/cell/fulltex...
Serotonin transporter inhibits antitumor immunity through regulating the intratumoral serotonin axis
Serotonin transporter (SERT) inhibits CD8 T cell antitumor immunity by depleting intratumoral
serotonin. SERT-blocking selective serotonin reuptake inhibitor (SSRI) antidepressants
enhance CD8 T cell ...
www.cell.com
May 21, 2025 at 11:46 PM
Can serotonin and SSRIs help T cells kill cancer?
Our @cp-cell.bsky.social article by Dr. Bo Li, doctoral candidate James Elsten-Brown and their team reports "Serotonin transporter inhibits antitumor immunity through regulating the intratumoral serotonin axis!" www.cell.com/cell/fulltex...
Our @cp-cell.bsky.social article by Dr. Bo Li, doctoral candidate James Elsten-Brown and their team reports "Serotonin transporter inhibits antitumor immunity through regulating the intratumoral serotonin axis!" www.cell.com/cell/fulltex...
Dr. Yan-Ruide Charlie Li and our doctoral students Yichen John Zhu and Yuning Christine Chen cover "The clinical landscape of CAR-engineered unconventional T cells" and the amazing therapeutic potential it holds in their review for
@cp-trendscancer.bsky.social
doi.org/10.1016/j.tr...
@cp-trendscancer.bsky.social
doi.org/10.1016/j.tr...
Redirecting
doi.org
May 21, 2025 at 12:48 AM
Dr. Yan-Ruide Charlie Li and our doctoral students Yichen John Zhu and Yuning Christine Chen cover "The clinical landscape of CAR-engineered unconventional T cells" and the amazing therapeutic potential it holds in their review for
@cp-trendscancer.bsky.social
doi.org/10.1016/j.tr...
@cp-trendscancer.bsky.social
doi.org/10.1016/j.tr...
Doctoral students Ying Fang and Yuning Christine Chen and their team discuss the promising "Biological functions and therapeutic applications of human mucosal-associated invariant T cells" in their review for @biomedcentral.bsky.social Journal of Biomedical Science
doi.org/10.1186/s129...
doi.org/10.1186/s129...
Biological functions and therapeutic applications of human mucosal-associated invariant T cells - Journal of Biomedical Science
Mucosal-associated invariant T (MAIT) cells are a unique subset of innate-like T lymphocytes that bridge innate and adaptive immunity. Characterized by their semi-invariant T cell receptor (TCR) and a...
doi.org
May 21, 2025 at 12:48 AM
Doctoral students Ying Fang and Yuning Christine Chen and their team discuss the promising "Biological functions and therapeutic applications of human mucosal-associated invariant T cells" in their review for @biomedcentral.bsky.social Journal of Biomedical Science
doi.org/10.1186/s129...
doi.org/10.1186/s129...
Dr. Yan-Ruide Li, Ying Fang, and their amazing teammates report their therapeutic innovations in "Allogeneic CD33-directed CAR-NKT cells for the treatment of bone marrow-resident myeloid malignancies" in their article for
@natcomms.nature.com
doi.org/10.1038/s414...
@natcomms.nature.com
doi.org/10.1038/s414...
Allogeneic CD33-directed CAR-NKT cells for the treatment of bone marrow-resident myeloid malignancies - Nature Communications
Yang and colleagues have previously reported a clinically guided culture method to generate allogeneic CAR-NKT cells by engineering human hematopoietic stem and progenitor cells. As potential applicat...
doi.org
May 21, 2025 at 12:46 AM
Dr. Yan-Ruide Li, Ying Fang, and their amazing teammates report their therapeutic innovations in "Allogeneic CD33-directed CAR-NKT cells for the treatment of bone marrow-resident myeloid malignancies" in their article for
@natcomms.nature.com
doi.org/10.1038/s414...
@natcomms.nature.com
doi.org/10.1038/s414...
Our amazing post-docs and doctoral students have made breakthroughs in "Generating allogeneic CAR-NKT cells for off-the-shelf cancer immunotherapy with genetically engineered HSP cells and feeder-free differentiation culture", as shown in @nature.com Protocols
doi.org/10.1038/s415...
doi.org/10.1038/s415...
Generating allogeneic CAR-NKT cells for off-the-shelf cancer immunotherapy with genetically engineered HSP cells and feeder-free differentiation culture - Nature Protocols
This protocol describes an ex vivo feeder-free culture method to differentiate genetically engineered hematopoietic stem and progenitor cells into allogeneic CAR-NKT cells for off-the-shelf cancer imm...
doi.org
May 21, 2025 at 12:45 AM
Our amazing post-docs and doctoral students have made breakthroughs in "Generating allogeneic CAR-NKT cells for off-the-shelf cancer immunotherapy with genetically engineered HSP cells and feeder-free differentiation culture", as shown in @nature.com Protocols
doi.org/10.1038/s415...
doi.org/10.1038/s415...
Exciting developments in the field of CAR-T therapies and the strategies to enhance it. Dr. Yan-Ruide Li and his team walk us through the state of the field and its promising future in their review on "Boosting CAR-T cell therapy through vaccine synergy" doi.org/10.1016/j.ti...
Redirecting
doi.org
May 21, 2025 at 12:42 AM
Exciting developments in the field of CAR-T therapies and the strategies to enhance it. Dr. Yan-Ruide Li and his team walk us through the state of the field and its promising future in their review on "Boosting CAR-T cell therapy through vaccine synergy" doi.org/10.1016/j.ti...